Headlines about Aytu Bioscience (NASDAQ:AYTU) have been trending somewhat positive on Tuesday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aytu Bioscience earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.9563291163597 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Aytu Bioscience (NASDAQ:AYTU) traded down $0.11 during trading hours on Tuesday, reaching $2.36. 16,231 shares of the company’s stock traded hands, compared to its average volume of 24,739. The stock has a market cap of $11.14, a P/E ratio of -0.07 and a beta of 4.37. Aytu Bioscience has a 12 month low of $2.05 and a 12 month high of $25.00.

Aytu Bioscience (NASDAQ:AYTU) last released its earnings results on Thursday, November 9th. The company reported ($1.76) earnings per share for the quarter, topping the consensus estimate of ($7.60) by $5.84. The company had revenue of $1.08 million for the quarter. Aytu Bioscience had a negative net margin of 481.06% and a negative return on equity of 229.64%.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Aytu Bioscience (AYTU) Share Price” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-aytu-bioscience-aytu-share-price/1800240.html.

Aytu Bioscience Company Profile

Aytu BioScience, Inc is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer.

Insider Buying and Selling by Quarter for Aytu Bioscience (NASDAQ:AYTU)

Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.